Lapine T-Lymphocyte Immune Globulin
Diamond-Blackfan Anemia
Explore 12 assets in Diamond-Blackfan Anemia →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04965597CT.gov Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diamond-Blackfan Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lapine T-Lymphocyte Immune Globulin (this asset) | Fred Hutchinson Cancer Center | P2 | CCC · 48 |
| Deferasirox | Novartis | P4 | BBB |
| Fludarabine | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Busulfanum | Paul Szabolcs | P2/3 | BBB |
| Cyclophosphamide | Paul Szabolcs | P2/3 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | BB |
| Methotrexate | Fred Hutchinson Cancer Center | P2 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Masonic Cancer Center, University of Minnesota | P2/3 | B |
| Alemtuzumab | Paul Szabolcs | P2 | B |
+16 more in the Diamond-Blackfan Anemia cohort
Other indications for Lapine T-Lymphocyte Immune Globulin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bone Marrow Failure Syndrome | — | P2 | CCC · 48 |
| Congenital Amegakaryocytic Thrombocytopenia | — | P2 | CCC · 48 |
| Inherited Sideroblastic Anemia | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lapine T-Lymphocyte Immune Globulin in Diamond-Blackfan Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lapine-t-lymphocyte-immune-globulin-diamond-blackfan-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →